Table 5. Main trends of clinical trials evaluating the efficacy of mitoxantrone as an off-label medication for cancer patients*.
| Location | Tumor type | Trials* | Phase | Notes |
|---|---|---|---|---|
|
Early clinical trials (phase I-II) | ||||
| Hematological tumors |
Lymphoma |
4 |
II |
Always in association with rituximab. |
| T-PLL |
1 |
II |
In association with alemtuzumab, cyclophosphamide and fludarabine. |
|
|
Advanced clinical trials(phase III-IV) | ||||
| Hematological tumors | Follicular lymphoma | 1 | III | In association with rituximab and fludarabine. |
Abbreviations: T-PLL, T-cell prolymphocytic leukemia. *n° of trials started after January, 1st 2008 and not completed or terminated at the day of submission.